As the domestic stock market continues its rebound, recovering from the previous day's sharp decline shock, pharmaceutical and biotech-related stocks are also showing overall strength. During the morning session on the 9th, buying interest flowed into the pharmaceutical and biotech sectors, primarily focusing on new drug development and bio-platform companies, leading major stocks to trend upward. On this day, both the KOSPI and KOSDAQ rose simultaneously, with a buy-side circuit breaker triggered in the KOSDAQ following the KOSPI, indicating a recovery in risk appetite across the broader market. Consequently, capital inflows into the pharmaceutical and biotech sectors have expanded.

Bio ventures and platform companies stood out. ABL Bio traded at 92,900 won, up 4.85% from the previous trading day, and rose to 93,100 won during the session, attracting investor attention. Rgenomics also showed strength, recording 91,600 won, a 4.33% increase. Peptron climbed to 242,500 won, up 5.21%, while Inventage Lab recorded a 7.26% surge to 44,350 won. SuSo Co., Ltd. also rose 7.69%, continuing the strong momentum within the biotech sector.

Large-cap and mid-to-small-cap pharmaceutical stocks also joined the upward trend. Yuhan Corp traded at 75,400 won, up 4.14%, while Dong-A ST and Boryung rose 3.79% and 3.28%, respectively. SK Chemicals also advanced 5.42%, reflecting the improved investor sentiment. Among mid-to-small-cap pharmaceutical stocks, Nature Cell recorded 30,550 won, up 3.74%, while Hyundai Pharm gained 4.17%, Yuyu Pharmaceutical rose 5.22%, and Jinyang Pharmaceutical increased by 4.26%. Dongkoo Bio & Pharma and CTC Bio also posted gains in the 4% range.

The market analysis suggests that following the previous day's plunge, low-priced buying has flowed into stocks that experienced excessive declines, allowing the biotech sector, which has strong growth stock characteristics, to participate in the rebound. In particular, as artificial intelligence (AI) technology has recently been increasingly applied to new drug development and clinical data analysis, interest in the overall biotech industry continues to grow. Evaluations indicate that expectations for global interest rate stability are further creating an investment environment favorable to growth stocks.

The securities industry advised that because stock prices within the biotech sector can vary significantly depending on technological development achievements and clinical progress, it is necessary to examine individual companies' research and development (R&D) results and business advancements, rather than simply following overall industry trends.

[This article was written based on publicly available market data and official materials, and utilized artificial intelligence (AI) in the process of drafting the article and organizing the information. The information provided in this article is intended for general investment information purposes and does not constitute a recommendation to invest in specific stocks or financial products. Investing in stock and financial markets carries the risk of principal loss, and all responsibility for investment decisions lies with the investor. Please be sure to check related disclosures and official materials before making an investment decision. This publication assumes no legal or financial responsibility for the information provided.]